Nabiximols (Sativex), a 1:1 THC:CBD oromucosal spray, is approved across Europe, Canada and elsewhere for multiple-sclerosis spasticity that resists standard treatment. Trials show real but modest responder rates — it helps a subset of patients, not everyone.